{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:31:25Z","timestamp":1790681485266,"version":"4.1.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"JSPS KAKENHI","award":["22K08091"],"award-info":[{"award-number":["22K08091"]}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20lm0203057h0003"],"award-info":[{"award-number":["JP20lm0203057h0003"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019702","name":"Tokyo Metropolitan Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019702","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Remarkable progress has been made in cancer immunotherapy, partly because of the development of immune checkpoint inhibitors. However, their efficacy varies across cancer types, with limited response observed in solid tumors, such as hepatocellular carcinoma (HCC). The primary cause of this low efficacy is insufficient infiltration of effector cells, such as cytotoxic CD8+ T cells, into the tumor tissue. This study investigated whether recombinant interleukin (rIL)-2, rIL-18, and antiprogrammed cell death-ligand 1 (\u03b1PD-L1) antibody (Ab) could serve as novel immunotherapies for HCC. Multidrug resistance gene 2-deficient mice, a spontaneously occurring liver cancer model associated with aging, were administered rIL-2, rIL-18, and \u03b1PD-L1Ab. Antitumor effects were evaluated using computed tomography and serum alpha-fetoprotein levels. Significant tumor shrinkage was observed in the rIL-2+rIL-18+\u03b1PD-L1Ab group, but not in the rIL-2+\u03b1PD-L1Ab or rIL-18+\u03b1PD-L1Ab groups. Concurrent administration of \u03b1CD8-neutralizing antibody abolished the antitumor effect, indicating CD8+ T-cell dependency. Spatial gene expression profiling revealed that intratumoral CD8+ effector T cells express and secrete CCL5 after treatment, promoting CD8+ T-cell mobilization to the liver and enhancing antitumor efficacy. Pretreatment with a CCL5 neutralizing antibody suppressed CD8+ cell infiltration into the tumor, eliminating the antitumor effect. The triple combination therapy used in this study promotes the infiltration and maintenance of CD8+ T cells in the liver, suggesting a promising new immunotherapy for HCC.<\/jats:p>","DOI":"10.1093\/pnasnexus\/pgag113","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T12:46:02Z","timestamp":1776257162000},"source":"Crossref","is-referenced-by-count":1,"title":["Combined administration of interleukin-2 and 18 with anti-PD-L1 antibody induces CCL5-positive CD8 T cells to suppress liver tumors"],"prefix":"10.1093","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3842-1703","authenticated-orcid":false,"given":"Masamichi","family":"Kimura","sequence":"first","affiliation":[{"name":"Department of Hepatology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital , Tokyo 113-8677 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenzaburo","family":"Yamaji","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Cell Biology, Tokyo Metropolitan Institute of Medical Science , Tokyo 156-8506 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Harada","sequence":"additional","affiliation":[{"name":"Department of Human Pathology, Kanazawa University Graduate School of Medical Sciences , Kanazawa 920-8640 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0575-0308","authenticated-orcid":false,"given":"Hideya","family":"Kawaji","sequence":"additional","affiliation":[{"name":"Research Center for Genome & Medical Sciences, Tokyo Metropolitan Institute of Medical Science , Tokyo 156-8506 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1189-2590","authenticated-orcid":false,"given":"Jun","family":"Imamura","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital , Tokyo 113-8677 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruki","family":"Okamura","sequence":"additional","affiliation":[{"name":"Laboratory of Tumor Immunology and Cell Therapy, Hyogo College of Medicine , Nishinomiya, Hyogo 663-8501 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5024-0614","authenticated-orcid":false,"given":"Yoshimasa","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Center for Medical Innovation, Nagasaki University , Nagasaki 852-8588 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2130-5837","authenticated-orcid":false,"given":"Michinori","family":"Kohara","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Cell Biology, Tokyo Metropolitan Institute of Medical Science , Tokyo 156-8506 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9352-4721","authenticated-orcid":false,"given":"Kiminori","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital , Tokyo 113-8677 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"2026042103512456300_pgag113-B1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2026042103512456300_pgag113-B2","doi-asserted-by":"crossref","first-page":"iv238","DOI":"10.1093\/annonc\/mdy308","article-title":"Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Vogel","year":"2018","journal-title":"Ann Oncol"},{"key":"2026042103512456300_pgag113-B3","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"N Engl J Med"},{"key":"2026042103512456300_pgag113-B4","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1136\/gutjnl-2013-306627","article-title":"Hepatocellular carcinoma: clinical frontiers and perspectives","volume":"63","author":"Bruix","year":"2014","journal-title":"Gut"},{"key":"2026042103512456300_pgag113-B5","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"2026042103512456300_pgag113-B6","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.immuni.2019.09.013","article-title":"TCF-1-centered transcriptional network drives an effector versus exhausted CD8 T cell-fate decision","volume":"51","author":"Chen","year":"2019","journal-title":"Immunity"},{"key":"2026042103512456300_pgag113-B7","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1146\/annurev.immunol.19.1.423","article-title":"Interleukin-18 regulates both Th1 and Th2 responses","volume":"19","author":"Nakanishi","year":"2001","journal-title":"Annu Rev Immunol"},{"key":"2026042103512456300_pgag113-B8","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/378088a0","article-title":"Cloning of a new cytokine that induces IFN-gamma production by T cells","volume":"378","author":"Okamura","year":"1995","journal-title":"Nature"},{"key":"2026042103512456300_pgag113-B9","doi-asserted-by":"crossref","first-page":"10702","DOI":"10.1128\/JVI.76.21.10702-10707.2002","article-title":"Interleukin-18 inhibits hepatitis B virus replication in the livers of transgenic mice","volume":"76","author":"Kimura","year":"2002","journal-title":"J Virol"},{"key":"2026042103512456300_pgag113-B10","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1084\/jem.20160880","article-title":"Inflammatory monocytes require type I interferon receptor signaling to activate NK cells via IL-18 during a mucosal viral infection","volume":"214","author":"Lee","year":"2017","journal-title":"J Exp Med"},{"key":"2026042103512456300_pgag113-B11","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1158\/1078-0432.CCR-15-1655","article-title":"Augmentation of immune checkpoint cancer immunotherapy with IL18","volume":"22","author":"Ma","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2026042103512456300_pgag113-B12","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1158\/0008-5472.CAN-05-2937","article-title":"Multiple adaptive mechanisms to chronic liver disease revealed at early stages of liver carcinogenesis in the Mdr2-knockout mice","volume":"66","author":"Katzenellenbogen","year":"2006","journal-title":"Cancer Res"},{"key":"2026042103512456300_pgag113-B13","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1158\/2326-6066.CIR-22-0398","article-title":"IL18 receptor signaling regulates tumor-reactive CD8+ T-cell exhaustion via activation of the IL2\/STAT5\/mTOR pathway in a pancreatic cancer model","volume":"11","author":"Lutz","year":"2023","journal-title":"Cancer Immunol Res"},{"key":"2026042103512456300_pgag113-B14","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41586-020-2422-6","article-title":"IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy","volume":"583","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"2026042103512456300_pgag113-B15","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/s41467-024-44795-1","article-title":"Macro CD5L(+) deteriorates CD8(+)T cells exhaustion and impairs combination of gemcitabine-oxaliplatin-lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinoma","volume":"15","author":"Lu","year":"2024","journal-title":"Nat Commun"},{"key":"2026042103512456300_pgag113-B16","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1002\/hep.26893","article-title":"Epitope-optimized alpha-fetoprotein genetic vaccines prevent carcinogen-induced murine autochthonous hepatocellular carcinoma","volume":"59","author":"Hong","year":"2014","journal-title":"Hepatology"},{"key":"2026042103512456300_pgag113-B17","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1126\/science.1198687","article-title":"Innate or adaptive immunity? The example of natural killer cells","volume":"331","author":"Vivier","year":"2011","journal-title":"Science"},{"key":"2026042103512456300_pgag113-B18","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S1471-4906(01)02060-9","article-title":"The biology of human natural killer-cell subsets","volume":"22","author":"Cooper","year":"2001","journal-title":"Trends Immunol"},{"key":"2026042103512456300_pgag113-B19","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.4049\/jimmunol.181.3.1627","article-title":"Cutting edge: priming of NK cells by IL-18","volume":"181","author":"Chaix","year":"2008","journal-title":"J Immunol"},{"key":"2026042103512456300_pgag113-B20","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1084\/jem.20021910","article-title":"Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function","volume":"197","author":"Curtsinger","year":"2003","journal-title":"J Exp Med"},{"key":"2026042103512456300_pgag113-B21","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nri778","article-title":"Effector and memory T-cell differentiation: implications for vaccine development","volume":"2","author":"Kaech","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"2026042103512456300_pgag113-B22","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/hep.26403","article-title":"Inflammation-induced hepatocellular carcinoma is dependent on CCR5 in mice","volume":"58","author":"Barashi","year":"2013","journal-title":"Hepatology"},{"key":"2026042103512456300_pgag113-B23","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nature02924","article-title":"NF-kappaB functions as a tumour promoter in inflammation-associated cancer","volume":"431","author":"Pikarsky","year":"2004","journal-title":"Nature"},{"key":"2026042103512456300_pgag113-B24","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.ccell.2019.05.004","article-title":"Cooperation between constitutive and inducible chemokines enables T cell engraftment and immune attack in solid tumors","volume":"35","author":"Dangaj","year":"2019","journal-title":"Cancer Cell"},{"key":"2026042103512456300_pgag113-B25","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1158\/0008-5472.CAN-12-4366","article-title":"IL-18-primed helper NK cells collaborate with dendritic cells to promote recruitment of effector CD8+ T cells to the tumor microenvironment","volume":"73","author":"Wong","year":"2013","journal-title":"Cancer Res"},{"key":"2026042103512456300_pgag113-B26","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.ccell.2016.03.005","article-title":"Tumoral immune cell exploitation in colorectal cancer metastases can be targeted effectively by anti-CCR5 therapy in cancer patients","volume":"29","author":"Halama","year":"2016","journal-title":"Cancer Cell"},{"key":"2026042103512456300_pgag113-B27","doi-asserted-by":"crossref","first-page":"e29244","DOI":"10.4161\/onci.29244","article-title":"Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes","volume":"3","author":"Robert","year":"2014","journal-title":"Oncoimmunology"},{"key":"2026042103512456300_pgag113-B28","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.4049\/jimmunol.1401184","article-title":"Synaptic release of CCL5 storage vesicles triggers CXCR4 surface expression promoting CTL migration in response to CXCL12","volume":"193","author":"Franciszkiewicz","year":"2014","journal-title":"J Immunol"},{"key":"2026042103512456300_pgag113-B29","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1038\/s41467-019-12464-3","article-title":"Single-cell transcriptomics of human T cells reveals tissue and activation signatures in health and disease","volume":"10","author":"Szabo","year":"2019","journal-title":"Nat Commun"},{"key":"2026042103512456300_pgag113-B30","doi-asserted-by":"crossref","first-page":"4467","DOI":"10.4049\/jimmunol.169.8.4467","article-title":"Synergistic engagement of an ineffective endogenous anti-tumor immune response and induction of IFN-gamma and Fas-ligand-dependent tumor eradication by combined administration of IL-18 and IL-2","volume":"169","author":"Wigginton","year":"2002","journal-title":"J Immunol"},{"key":"2026042103512456300_pgag113-B31","doi-asserted-by":"crossref","first-page":"e1002273","DOI":"10.1371\/journal.ppat.1002273","article-title":"Exhausted CD8 T cells downregulate the IL-18 receptor and become unresponsive to inflammatory cytokines and bacterial co-infections","volume":"7","author":"Ingram","year":"2011","journal-title":"PLoS Pathog"},{"key":"2026042103512456300_pgag113-B32","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.1038\/s41467-021-24734-0","article-title":"CD8(+) tissue-resident memory T cells promote liver fibrosis resolution by inducing apoptosis of hepatic stellate cells","volume":"12","author":"Koda","year":"2021","journal-title":"Nat Commun"}],"container-title":["PNAS Nexus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pnasnexus\/advance-article-pdf\/doi\/10.1093\/pnasnexus\/pgag113\/68085609\/pgag113.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pnasnexus\/article-pdf\/5\/4\/pgag113\/68085609\/pgag113.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pnasnexus\/article-pdf\/5\/4\/pgag113\/68085609\/pgag113.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T07:51:38Z","timestamp":1776757898000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pnasnexus\/article\/doi\/10.1093\/pnasnexus\/pgag113\/8654300"}},"subtitle":[],"editor":[{"given":"Christof","family":"Niehrs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,7]]}},"URL":"https:\/\/doi.org\/10.1093\/pnasnexus\/pgag113","relation":{},"ISSN":["2752-6542"],"issn-type":[{"value":"2752-6542","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,4]]},"article-number":"pgag113"}}